KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ClearPoint Neuro (CLPT) Change in Accured Expenses (2018 - 2025)

ClearPoint Neuro (CLPT) has disclosed Change in Accured Expenses for 13 consecutive years, with -$6.3 million as the latest value for Q4 2025.

  • Quarterly Change in Accured Expenses fell 461.95% to -$6.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$7.5 million through Dec 2025, down 342.19% year-over-year, with the annual reading at -$7.5 million for FY2025, 342.19% down from the prior year.
  • Change in Accured Expenses hit -$6.3 million in Q4 2025 for ClearPoint Neuro, down from $693000.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $1.7 million in Q4 2024 to a low of -$6.3 million in Q4 2025.
  • Historically, Change in Accured Expenses has averaged -$109400.0 across 5 years, with a median of $355000.0 in 2022.
  • Biggest YoY gain for Change in Accured Expenses was 443.4% in 2022; the steepest drop was 1181.48% in 2022.
  • Year by year, Change in Accured Expenses stood at -$133000.0 in 2021, then soared by 352.63% to $336000.0 in 2022, then grew by 11.31% to $374000.0 in 2023, then surged by 363.1% to $1.7 million in 2024, then crashed by 461.95% to -$6.3 million in 2025.
  • Business Quant data shows Change in Accured Expenses for CLPT at -$6.3 million in Q4 2025, $693000.0 in Q3 2025, and $938000.0 in Q2 2025.